Log In
BCIQ
Print this Print this
 

Glucagon nasal powder (formerly 1060-P)

  Manage Alerts
Collapse Summary General Information
Company Eli Lilly and Co.
DescriptionDry powder intranasal glucagon
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase III
Standard IndicationHypoglycemia
Indication DetailsTreat severe hypoglycemia in Type I diabetics ages 4-16
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$150.0M

$150.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/09/2015

$150.0M

$150.0M

0

Get a free BioCentury trial today